Novo Nordisk cuts Wegovy, Ozempic direct-to-user prices to match Eli Lilly’s Zepbound

Novo Nordisk (NVO) is cutting prices to challenge rival Eli Lilly (LLY) in the obesity-drug market, signaling a more ...